Tag: aspirin

1. Patients status-post placement of drug-eluting stents (DES) for acute coronary syndrome received three months of Ticagrelor and Aspirin dual-antiplatelet therapy (DAPT), followed by nine months of DAPT or Ticagrelor monotherapy. 2. At one year, patients who received Ticagrelor alone experienced significantly fewer adverse major bleeding events. There was no...

1. Ticagrelor and aspirin taken after a mild-to-moderate acute non-cardioembolic stroke or high-risk transient ischemic attack led to a lower rate of subsequent stroke within 30 days. 2. The incidence of overall disability at 30 days did not differ between groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Following an acute ischemic...

1. Patients status-post placement of drug-eluting stents (DES) for acute coronary syndrome received three months of Ticagrelor and Aspirin dual-antiplatelet therapy (DAPT), followed by nine months of DAPT or Ticagrelor monotherapy. 2. At one year, patients who received Ticagrelor alone experienced significantly fewer adverse major bleeding events. There was no...

1. Aspirin (100mg daily) was not found to be effective in preventing depression in healthy older adults. Evidence Rating Level: 2 (Good) Depression is a common mental health condition, accounting for a significant portion of disability cases in both young and older populations. Due to the confirmed role of immune...

1. In this pre-specified ancillary study of a randomized control trial, ticagrelor alone after one month was found non-inferior, but not superior, to dual antiplatelet therapy in preventing ischemic events after drug eluting coronary stenting. 2. Ticagrelor did not decrease bleeding risk compared with dual antiplatelet therapy. Evidence Rating Level: 2...

1. The benefit of daily aspirin varied dramatically depending on whether one cardiovascular disease event was equivalent to one or two bleeding events 2. Subgroups that tended to benefit more from aspirin treatment included patients with cardiovascular disease risk factors such as hyperlipidemia, hypertension, diabetes, smokers) and those with lower...

1. The benefit of daily aspirin varied dramatically depending on whether one cardiovascular disease event was equivalent to one or two bleeding events 2. Subgroups that tended to benefit more from aspirin treatment included patients with cardiovascular disease risk factors such as hyperlipidemia, hypertension, diabetes, smokers) and those with lower...

Aspirin (ASA) continues to be used for the primary prevention of cardiovascular disease (CVD) in patients at increased risk, despite evidence consistently demonstrating little benefit in cardiovascular event reduction and increased bleeding risk. Accordingly, the American Heart Association and American College of Cardiology (AHA/ACC) released new guidelines recommending against...

Roxadustat for anemia in patients with kidney disease not receiving dialysis Chronic kidney disease (CKD)-related anemia is associated with significant morbidity, and remains undertreated worldwide. Adequate treatment of CKD-related anemia is associated with reduced transfusion rates and improved clinical outcomes. Roxadustat is a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that...

While dual antiplatelet therapy (DAPT) is the standard of care post-percutaneous coronary intervention (PCI) using drug-eluting stents (DES), the optimal duration of therapy remains controversial. American and European guidelines recommend DAPT for a minimum of 12 months for acute coronary syndrome (ACS), and at least 6 months in stable...